Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KALEXATE vs ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
KALEXATE is a monoclonal antibody that binds to both soluble and membrane-bound human interleukin-6 (IL-6) receptors, inhibiting IL-6-mediated signaling. IL-6 is a pro-inflammatory cytokine implicated in the pathogenesis of rheumatoid arthritis and other inflammatory conditions.
Acetaminophen: cyclooxygenase (COX) inhibitor, primarily central, analgesic and antipyretic. Aspirin: irreversible COX-1 and COX-2 inhibitor, analgesic, anti-inflammatory, antipyretic, antiplatelet. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.
Treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs),Treatment of giant cell arteritis in adult patients
Mild to moderate pain,Fever (acetaminophen and aspirin),Inflammatory conditions (aspirin)
10 mg orally once daily.
1-2 tablets (each containing acetaminophen 300 mg, aspirin 300 mg, codeine phosphate 30 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets/day.
12-15 hours; prolonged in renal impairment (up to 30 hours in severe cases)
Acetaminophen: 2-3 hours (terminal). Aspirin: 15-30 minutes (parent drug); salicylate: 2-3 hours at low doses, 15-30 hours at high doses due to saturable metabolism. Codeine: 2.5-4 hours. Clinical context: Prolonged half-life of salicylate at high doses increases risk of toxicity; hepatic impairment prolongs acetaminophen and codeine half-lives.
KALEXATE is a monoclonal antibody; it is catabolized into small peptides and amino acids via general protein degradation pathways. No specific metabolic enzymes or pathways are involved.
Acetaminophen: hepatic via CYP2E1, CYP1A2, CYP3A4; glucuronidation and sulfation; NAPQI formation. Aspirin: hepatic hydrolysis to salicylate; conjugation with glycine and glucuronic acid. Codeine: hepatic via CYP2D6 to morphine (active); also via CYP3A4 to norcodeine.
Primarily renal (75-80% as unchanged drug); biliary/fecal (15-20%)
Acetaminophen: renal excretion of metabolites (glucuronide and sulfate conjugates, ~85-90%), minor parent drug (<5%). Aspirin: renal excretion of salicylate and its metabolites (salicyluric acid, glucuronides, gentisic acid), dose-dependent; at therapeutic doses, ~50-80% as free salicylate and conjugates. Codeine: renal excretion of free and conjugated codeine (about 90%) and metabolites (morphine, norcodeine).
60-70% primarily to albumin
Acetaminophen: 10-25% (albumin). Aspirin: 50-80% (albumin), dose-dependent; salicylate: 75-90% (albumin). Codeine: ~7% (albumin).
1.2-1.6 L/kg; indicates extensive extravascular distribution
Acetaminophen: 0.9-1.0 L/kg (large distribution including liver). Aspirin: 0.15-0.2 L/kg (low Vd, confined to plasma and extracellular fluid); salicylate: 0.2-0.3 L/kg. Codeine: 3-6 L/kg (extensive tissue distribution). Clinical meaning: Large Vd for codeine suggests extensive tissue binding; aspirin Vd is small, consistent with limited extravascular distribution.
Oral: 85-95%
Oral: Acetaminophen: 85-95%. Aspirin: 40-60% (due to first-pass hydrolysis to salicylate). Codeine: ~50% due to first-pass metabolism.
GFR >= 60 m L/min: no adjustment; GFR < 60 m L/min: use not recommended.
GFR 30-59 m L/min: Administer every 6 hours; maximum 6 tablets/day. GFR 15-29 m L/min: Administer every 12 hours; maximum 4 tablets/day. GFR <15 m L/min: Not recommended due to accumulation of codeine metabolites.
Child-Pugh A: 5 mg once daily; Child-Pugh B: 2.5 mg once daily; Child-Pugh C: not recommended.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50% and extend interval to every 6 hours; maximum 4 tablets/day. Child-Pugh Class C: Contraindicated.
Not approved for pediatric use.
Not recommended for children <12 years due to aspirin risk of Reye syndrome. For children ≥12 years: Dose based on codeine component (0.5-1 mg/kg/dose) with maximum acetaminophen 75 mg/kg/day and aspirin 100 mg/kg/day. Typical: 1 tablet (acetaminophen 300 mg/aspirin 300 mg/codeine 30 mg) every 4-6 hours as needed; max 4 tablets/day.
No specific dose adjustment; monitor renal function.
Start with lowest effective dose (e.g., 1 tablet every 6 hours); monitor renal and hepatic function; maximum 6 tablets/day due to increased sensitivity and risk of adverse effects.
Risk of serious infections including tuberculosis, invasive fungal infections, and other opportunistic pathogens. Patients should be screened for latent tuberculosis prior to initiation. If serious infection develops, interrupt KALEXATE until infection is controlled.
Risk of medication errors: confusion between different strengths and concentrations of acetaminophen can result in accidental overdose and fatal hepatotoxicity. Aspirin use in children and teenagers with viral infections is associated with Reye's syndrome.
Serious infections,Hepatotoxicity (elevated liver enzymes),Neutropenia,Thrombocytopenia,Lipid elevations,Gastrointestinal perforation (risk higher in patients with diverticulitis),Hypersensitivity reactions,Live vaccines should not be given concurrently
Hepatotoxicity (acetaminophen dose >4 g/day), Reye's syndrome (aspirin in children), respiratory depression (codeine), tolerance/dependence, bleeding risk (aspirin), GI toxicity, renal impairment, hypersensitivity reactions.
Known hypersensitivity to KALEXATE or any of its excipients,Active infections including localized infections
Hypersensitivity to any component, active peptic ulcer disease, bleeding disorders, severe hepatic impairment, severe respiratory depression, children with viral illness (aspirin), pregnancy (third trimester for aspirin, codeine cautious).
Avoid potassium-rich foods (bananas, oranges, potatoes, spinach, tomatoes, salt substitutes). Do not mix with fruit juices containing high potassium (e.g., orange, tomato). Maintain adequate fluid intake to prevent constipation.
Avoid alcohol due to increased risk of acetaminophen hepatotoxicity and aspirin-induced GI bleeding. Avoid large amounts of caffeine or high-tyramine foods (e.g., aged cheeses, cured meats) as they may affect CYP2D6 metabolism of codeine.
Kalexate (sodium polystyrene sulfonate) is not absorbed systemically and thus has no direct fetal exposure. However, electrolyte disturbances from maternal use (hypokalemia, hypernatremia) may indirectly affect fetal development. No specific teratogenic risk is documented; avoid severe maternal electrolyte imbalances.
Acetaminophen: Generally considered low risk; association with ASD and ADHD with prolonged use not fully established. Aspirin: First trimester: possible increased risk of gastroschisis; second trimester: relatively safe; third trimester: risk of premature closure of ductus arteriosus, oligohydramnios, and increased peripartum hemorrhage. Codeine: First trimester: possible neural tube defects; second and third trimesters: risk of respiratory depression, withdrawal in neonate with chronic use; neonatal opioid withdrawal syndrome (NOWS) possible.
Kalexate is not absorbed from the gastrointestinal tract, so systemic concentrations are negligible. M/P ratio is not applicable. Considered compatible with breastfeeding, but monitor infant for electrolyte imbalance if maternal use is prolonged.
Acetaminophen: M/P ratio approximately 0.91-1.42; considered safe. Aspirin: M/P ratio 0.08-0.15; high doses may cause Reye's syndrome; avoid or use low doses. Codeine: M/P ratio about 2.5; variable metabolism; risk of CNS depression in infant; avoid due to potential for toxicity in CYP2D6 ultrarapid metabolizers.
Standard dosing (15-60 g orally per day) may be used in pregnancy. No pharmacokinetic changes requiring dose adjustment as the drug is not absorbed. However, monitor electrolytes more frequently due to pregnancy-related volume expansion and altered renal function.
Acetaminophen: No dose adjustment needed. Aspirin: Avoid in third trimester; use lowest effective dose if necessary. Codeine: Avoid in pregnancy; if used, lowest effective dose for shortest duration; caution for CYP2D6 polymorphism. Pharmacokinetic changes: Increased clearance of codeine during pregnancy may require higher doses but risk outweighs benefit.
Kalexate (sodium polystyrene sulfonate) exchanges sodium for potassium in the gastrointestinal tract. Onset of action is 2-12 hours. Avoid in patients with hypokalemia, severe hypernatremia, or bowel obstruction. Monitor serum potassium and sodium levels regularly. Use with caution in patients with congestive heart failure or severe edema due to sodium load. Administer orally or as a retention enema; do not mix with fruit juices containing high potassium (e.g., orange juice).
Combination analgesic with acetaminophen (hepatotoxic at high doses), aspirin (antiplatelet, GI irritant, contraindicated in children <12 due to Reye's syndrome), and codeine (prodrug to morphine via CYP2D6; efficacy depends on CYP2D6 phenotype; risk of CNS/respiratory depression). Avoid in severe hepatic/renal impairment, active peptic ulcer, bleeding disorders, or concomitant use of other CNS depressants. Maximum acetaminophen dose from all sources: 4 g/day.
Take this medication exactly as prescribed to lower high potassium levels.,Do not mix with orange juice or other high-potassium beverages.,Drink plenty of water with each dose to prevent constipation.,Report any signs of bowel obstruction (severe abdominal pain, vomiting, no bowel movements) immediately.,Notify your doctor if you experience irregular heartbeat, muscle weakness, or numbness/tingling.,This medication contains sodium; inform your doctor if you have heart failure or high blood pressure.
Do not exceed recommended dose; acetaminophen overdosage can cause serious liver damage.,Do not take with other products containing acetaminophen or aspirin.,Avoid alcohol while taking this medication to reduce risk of liver toxicity and GI bleeding.,This product contains aspirin; do not give to children/teenagers with chickenpox or flu-like symptoms to avoid Reye's syndrome.,May cause drowsiness; do not drive or operate machinery until you know how you react.,Codeine is a narcotic pain reliever with abuse potential; use exactly as prescribed.,Seek medical attention if you experience signs of allergic reaction (rash, difficulty breathing) or bleeding (black/tarry stools, unusual bruising).
No interactions on record
"Pirenzepine, a selective M1 muscarinic antagonist, reduces gastrointestinal motility and secretions, while codeine, an opioid agonist, also decreases gastrointestinal motility via mu-opioid receptors. Concurrent use leads to additive anticholinergic and opioid effects, resulting in enhanced risk of severe constipation, paralytic ileus, and central nervous system depression. Clinically, patients may experience exacerbated sedation, respiratory depression, and urinary retention."
"Ropinirole, a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome, may reduce the analgesic efficacy of codeine. This is likely due to pharmacodynamic antagonism at central dopamine and opioid receptors, as well as potential pharmacokinetic interactions that decrease the conversion of codeine to its active metabolite morphine via CYP2D6 inhibition by ropinirole. The resultant blunted opioid response can lead to inadequate pain control, necessitating dose adjustment or alternative therapy."
"Vemurafenib induces CYP3A4, significantly reducing the plasma concentrations of codeine, which is metabolized via CYP3A4 to its active metabolite morphine. This may diminish codeine's analgesic efficacy, potentially leading to inadequate pain control. Additionally, reduced formation of morphine may lower the risk of opioid-related adverse effects."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KALEXATE vs ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE, answered by our medical review team.
KALEXATE is a SSRI Antidepressant that works by KALEXATE is a monoclonal antibody that binds to both soluble and membrane-bound human interleukin-6 (IL-6) receptors, inhibiting IL-6-mediated signaling. IL-6 is a pro-inflammatory cytokine implicated in the pathogenesis of rheumatoid arthritis and other inflammatory conditions.. ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE is a Opioid Agonist that works by Acetaminophen: cyclooxygenase (COX) inhibitor, primarily central, analgesic and antipyretic. Aspirin: irreversible COX-1 and COX-2 inhibitor, analgesic, anti-inflammatory, antipyretic, antiplatelet. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KALEXATE and ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KALEXATE is: 10 mg orally once daily.. The standard adult dose of ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE is: 1-2 tablets (each containing acetaminophen 300 mg, aspirin 300 mg, codeine phosphate 30 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KALEXATE and ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KALEXATE is classified as Category C. Kalexate (sodium polystyrene sulfonate) is not absorbed systemically and thus has no direct fetal exposure. However, electrolyte disturbances from maternal use (hypokalemia, hypern. ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE is classified as Category D/X. Acetaminophen: Generally considered low risk; association with ASD and ADHD with prolonged use not fully established. Aspirin: First trimester: possible increased risk of gastrosch. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.